Victoria: A multicentric, randomized, open-label, phase I/II of mTOR inhibitor (VISTUSERTIB) combined with anastrozole in patients with hormone receptor-positive advanced/metastatic endometrial cancer-A CLIPP program INCA in collaboration with GINECO grou

Affiliation auteurs!!!! Error affiliation !!!!
TitreVictoria: A multicentric, randomized, open-label, phase I/II of mTOR inhibitor (VISTUSERTIB) combined with anastrozole in patients with hormone receptor-positive advanced/metastatic endometrial cancer-A CLIPP program INCA in collaboration with GINECO grou
Type de publicationJournal Article
Year of Publication2021
AuteursHeudel P-E, Frenel J-S, Dalban C, Bazan F, Joly F, Arnaud A, Abdeddaim C, Chevalier A, Augereau P, Pautier P, Chakiba C, You B, Lecomte LLancry, Garin G, MArcel V, Diaz J-J, Treilleux I, Perol D, Fabbro M, Ray-Coquard ILaure
JournalJOURNAL OF CLINICAL ONCOLOGY
Volume39
Date PublishedMAY 20
Type of ArticleMeeting Abstract
ISSN0732-183X
DOI10.1200/JCO.2021.39.15_suppl.5507